All lobbying filings

THE NICKLES GROUP, LLC

THE NICKLES GROUP, LLC filed a Q3 report for OMEROS CORPORATION on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for OMEROS CORPORATION · Biopharmaceutical company.

All filings by THE NICKLES GROUP, LLC · Everything OMEROS CORPORATION has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Washington

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Issues involving rare disease therapies.

Health Issues

Issues related to rare pediatric disease and Priority Review Vouchers (PRVs). H.R. 10359, Priority for Pediatric Cures Act.

Bills named in this filing 1

H.R. 10359
Priority for Pediatric Cures Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.